Skip to main content
. 2021 Apr 27;13(9):2112. doi: 10.3390/cancers13092112

Figure 5.

Figure 5

Treatment with relatlimab depletes leukemic cells. (A) PBMCs from 26 patients with CLL were treated with relatlimab or isotype control (10 µg/mL) and absolute leukemic cell count was performed at indicated timepoints. Bars represent the percentage of leukemic cells normalized to control; (B) Intracellular staining and flow cytometry analysis for Bcl-2 expression (normalized to control) were performed in PBMCs treated with relatlimab or isotype control (10 µg/mL) for 72 h or 7 days (n = 8); (C) Evaluation of absolute leukemic cell count (normalized to control) in PBMCs from patients treated with relatlimab or isotype control (10 µg/mL), alone or in combination with lenalidomide (LND) (10 µM), for 72 h (n = 12); (D) Effect of LAG-3 blockade on NK cell-mediated cytotoxicity was evaluated by calcein-AM assay in PBMCs from 10 patients treated with relatlimab (10 µg/mL), alone or in combination with lenalidomide (LND; 10 µM), and co-cultured with MEC-I CLL-derived cell line at 25:1 (E:T) ratio (n = 10) for 72 h. ADCC was evaluated by pre-treating target MEC-I cells with rituximab (10 µg/mL). * p < 0.05, ** p < 0.01 and *** p < 0.001.